Invitrogen™ Sonepcizumab Recombinant Monoclonal Antibody

Sonepcizumab, also referred to as LT1009, is a humanized monoclonal antibody that targets sphingosine 1-phosphate (S1P), a signaling lipid active in promoting angiogenesis and tumor growth. Sphingosine-1-phosphate (S1P) is a critical lysolipid involved in multiple biological functions, including heart development, immune response, and hearing. It is a metabolite from cell membrane sphingolipids and is primarily regulated through its binding to specific G protein-coupled receptors named S1P receptors (S1PRs). These receptors are ubiquitously expressed in the human body, influencing various physiological and pathological processes. The signaling pathways initiated by S1P-S1PR interactions are crucial for immune cell trafficking, activation, and adaptive immune responses. Studies also highlight the role of S1P in regulating vascular stability, endothelial cell function, and as a mediator in inflammatory responses. The SPNS2 gene encodes a transporter protein essential for the active secretion of S1P, further emphasizing its relevance in maintaining physiological homeostasis.